A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer

被引：0
|
作者：
Caputo, Emilia [1 ]
机构：
[1] CNR, Inst Genet & Biophys IGB A Buzzati Traverso, Via Pietro Castellino 111, I-80131 Naples, Italy
来源：
THERANOSTICS | 2017年 / 7卷 / 07期
关键词：
D O I：
10.7150/thno.20460
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Cancer is a very complex disease, where cell alterations (i.e. gene mutations, dysregulated signaling pathway(s) and epigenetic modifications) contribute to its development and progression. Elucidating the connections among these cell modifications is a critical challenge, in order to understand the mechanisms which are activated from cancer cells to survive and proliferate. Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
引用
收藏
页码：2108 / 2110
页数：3
相关论文
共 50 条
  • [21] Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation reply
    Tang, Hsin-Chieh
    Chen, Yu-Chian
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10
  • [22] Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation
    Liang, Shile
    Sharma, Arati
    Peng, Hsin-Hsin
    Robertson, Gavin
    Dong, Cheng
    CANCER RESEARCH, 2007, 67 (12) : 5814 - 5820
  • [23] A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies
    Yao, Kevin
    Zhou, Emily
    Cheng, Chao
    CANCER MEDICINE, 2022, 11 (04): : 1232 - 1243
  • [24] Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    Ramin Nazarian
    Hubing Shi
    Qi Wang
    Xiangju Kong
    Richard C. Koya
    Hane Lee
    Zugen Chen
    Mi-Kyung Lee
    Narsis Attar
    Hooman Sazegar
    Thinle Chodon
    Stanley F. Nelson
    Grant McArthur
    Jeffrey A. Sosman
    Antoni Ribas
    Roger S. Lo
    Nature, 2010, 468 : 973 - 977
  • [25] B-RAF V600E MUTATION IS A PROGNOSTIC FACTOR IN STAGE II AND III COLON CARCINOMA PATIENTS
    Farina, A.
    Moerland, E.
    Van Lijnschoten, G.
    Creemers, G. J.
    Lemmens, V. E. P. P.
    Rutten, H. J. T.
    Van den Brule, A. J. C.
    ANNALS OF ONCOLOGY, 2010, 21 : I17 - I18
  • [26] Anti-DLL4 reduces tumor growth and tumorigenicity in B-RAF V600E melanomas including those with acquired resistance to B-RAF inhibitors
    Beviglia, Lucia
    Yeung, Pete
    Fischer, Marcus
    Yen, Wang-Ching
    Gurney, Austin
    Lewicki, John
    Kapoun, Ann
    Hoey, Timothy
    CANCER RESEARCH, 2012, 72
  • [27] Absence of V600E B-RAF Mutation in MLH1-Negative Endometrial Carcinoma.
    Musulen, E.
    Munoz-Marmol, A. M.
    Sanz, C.
    Carrato, C.
    Mate, J. L.
    Ariza, A.
    LABORATORY INVESTIGATION, 2011, 91 : 261A - 261A
  • [28] B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules
    Bentz, Brandon G.
    Miller, Brian T.
    Holden, Joseph A.
    Rowe, Leslie R.
    Bentz, Joel S.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2009, 140 (05) : 709 - 714
  • [29] The mechanism of activation of monomeric B-Raf V600E.
    Maloney, Ryan C.
    Zhang, Mingzhen
    Jang, Hyunbum
    Nussinov, Ruth
    CANCER RESEARCH, 2021, 81 (13)
  • [30] Primary pineal malignant melanoma with B-Raf V600E mutation: a case report and brief review of the literature
    Kathleen Jetschke
    Heike Viehweger
    Martin Freesmeyer
    Jan-Peter Warnke
    Christian Mawrin
    Acta Neurochirurgica, 2015, 157 : 1267 - 1270
12345